TABLE 3.
Human plasma and CSF MS results for patients 1, 2, and 3 after oral dosing at 100 mg twice dailya
| Compartment or parameter | Concn (ng/ml) or ratio |
||||||
|---|---|---|---|---|---|---|---|
| Patient 1 |
Patient 2 |
Patient 3 |
|||||
| DLM (lab 1) | DLM (lab 2) | DM-6705 | DLM (lab 1) | DM-6705 | DLM (lab 1) | DM-6705 | |
| Plasma (0 h) | 550 | 773.5 | 109.3 | 465 | NT | 450 | NT |
| Plasma (2 h) | 450 | 572.6 | 86.3 | 500 | NT | 580 | NT |
| Plasma (4 h) | 750 | 1,082.8 | 96.3 | 473 | NT | 600 | NT |
| Plasma (7 h) | 740 | 848.3 | 95 | 481 | NT | 510 | NT |
| CSF (4 h) | BLQ | 1.8 | 0.8 | 33 | NT | 110 | NT |
| CSF/plasma ratio (4 h) | <0.01 | < 0.01 | 0.07 | 0.18 | |||
a
Concentrations were initially measured at lab 1. Samples from patient 1 were also sent to lab 2 so that DM-6705 could be measured. BLQ, below the limit of detection; NT, not tested.